Compositions and methods for using engineered deubiquitinases for probing ubiquitin-dependent cellular processes

US11845967B2 · kind B2 · utility

Assignee

• The Trustees of Columbia University in the City of New York · US

Inventors

• Henry M. Colecraft · Pages Corner, US
• Scott Kanner · New York, US

Key dates

• Filing date: May 6, 2020
• Grant date: Dec 19, 2023
• Expiry date: Jun 29, 2041

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2800/382
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure provides, inter alia, a recombinant engineered deubiquitinase (DUB) and methods for treating or ameliorating an inherited ion channelopathy, such as long QT syndrome, Brugada syndrome, or cystic fibrosis, in a subject. Further provided are methods for screening mutations causing such inherited ion channelopathies for a trafficking-deficient mutation that is treatable by the recombinant engineered DUB disclosed herein.